What is the address of Van Looveren RX, radiologie BV?

The registered office of Van Looveren RX, radiologie BV is located at De Nachtegaal 42, 2970 Schilde.

Is Van Looveren RX, radiologie BV still active?

Yes. According to the CBE (29 September 2026) Van Looveren RX, radiologie BV is active, legal situation “Normale toestand”, started on 8 October 2019.

Is Van Looveren RX, radiologie BV registered on Peppol?

Yes, Van Looveren RX, radiologie BV is registered on the Peppol network with ID 0208:0735850611.

What is the enterprise number of Van Looveren RX, radiologie BV?

The enterprise number of Van Looveren RX, radiologie BV is BE0735850611.

When was Van Looveren RX, radiologie BV founded?

Van Looveren RX, radiologie BV was founded on 8 October 2019.

Who are the directors of Van Looveren RX, radiologie BV?

According to the 2025 annual accounts, the directors of Van Looveren RX, radiologie BV are: Kevin Van Looveren.

Is Van Looveren RX, radiologie BV a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 8 October 2019; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did Van Looveren RX, radiologie BV make in 2025?

Van Looveren RX, radiologie BV posted a profit after taxes of € 604,954 in financial year 2025.

What is the revenue of Van Looveren RX, radiologie BV?

As a small company, Van Looveren RX, radiologie BV is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 832,531.

How many employees does Van Looveren RX, radiologie BV have?

According to the 2025 annual accounts, Van Looveren RX, radiologie BV has 0 full-time equivalents (FTE).

Van Looveren RX, radiologie BV (Private Limited)

Dossier Van Looveren RX, radiologie BV, printed on 29 September 2026 from databakkes.be/en/0735850611/van-looveren-rx-radiologie-bv. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 1 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

Van Looveren RX, radiologie BV from Schilde, company number BE0735850611, closed financial year 2025 with a result of € 604,954 after tax. For that financial year Van Looveren RX, radiologie BV recorded a gross margin of € 832,531 and equity of € 100. Compared with financial year 2024, the result moved from € 616,123 to € 604,954. The company is profitable. The buffer shrank hard: equity is 100 % below last year. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on April 28, 2026.

What it is worth Shrank hard

€ 100

▼ € 616,123 vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 604,954

▼ 2% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 8,742

▼ 89% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 1.2 million paid out

More than the year’s profit went to the shareholders; reserves fell.

People and assets in 2025

Full-time equivalents

Average over the fiscal year, from the social balance sheet.

Vehicles and equipment

€ 19,257

▲ 119% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 357

▼ 16% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 16,008

▲ 23% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 707,073 Gross margin 2022: € 707,073 First fiscal year in the series	€ 788,369 Gross margin 2023: € 788,369 ▲ 11% vs 2022 (€ 707,073) Favourable step	€ 833,063 Gross margin 2024: € 833,063 ▲ 6% vs 2023 (€ 788,369) Favourable step	€ 832,531 Gross margin 2025: € 832,531 Unchanged (€ 833,063) Unfavourable step
Profit after taxes	€ 518,348 Profit after taxes 2022: € 518,348 First fiscal year in the series	€ 584,491 Profit after taxes 2023: € 584,491 ▲ 13% vs 2022 (€ 518,348) Favourable step	€ 616,123 Profit after taxes 2024: € 616,123 ▲ 5% vs 2023 (€ 584,491) Favourable step	€ 604,954 Profit after taxes 2025: € 604,954 ▼ 2% vs 2024 (€ 616,123) Unfavourable step	▼ 2%
Equity	€ 518,487 Equity 2022: € 518,487 First fiscal year in the series	€ 584,591 Equity 2023: € 584,591 ▲ 13% vs 2022 (€ 518,487) Favourable step	€ 616,223 Equity 2024: € 616,223 ▲ 5% vs 2023 (€ 584,591) Favourable step	€ 100 Equity 2025: € 100 ▼ € 616,123 vs 2024 (€ 616,223) Unfavourable step	▼ € 616,123
Total debts	€ 191,512 Total debts 2022: € 191,512 First fiscal year in the series	€ 242,352 Total debts 2023: € 242,352 ▲ 27% vs 2022 (€ 191,512) Unfavourable step	€ 49,669 Total debts 2024: € 49,669 ▼ 80% vs 2023 (€ 242,352) Favourable step	€ 610,813 Total debts 2025: € 610,813 ▲ € 561,145 vs 2024 (€ 49,669) Unfavourable step	▲ € 561,145
Cash	€ 203,578 Cash 2022: € 203,578 First fiscal year in the series	€ 303,231 Cash 2023: € 303,231 ▲ 49% vs 2022 (€ 203,578) Favourable step	€ 80,600 Cash 2024: € 80,600 ▼ 73% vs 2023 (€ 303,231) Unfavourable step	€ 8,742 Cash 2025: € 8,742 ▼ 89% vs 2024 (€ 80,600) Unfavourable step	▼ 89%
Retained profit	€ 518,387 Retained profit 2022: € 518,387 First fiscal year in the series	€ 584,491 Retained profit 2023: € 584,491 ▲ 13% vs 2022 (€ 518,387) Favourable step	€ 616,123 Retained profit 2024: € 616,123 ▲ 5% vs 2023 (€ 584,491) Favourable step	€ 0 Retained profit 2025: € 0 ▼ 100% vs 2024 (€ 616,123) Unfavourable step	▼ 100%
Dividend	€ 899,400 Dividend 2022: € 899,400 First fiscal year in the series	€ 518,387 Dividend 2023: € 518,387 ▼ 42% vs 2022 (€ 899,400) Unchanged	€ 584,491 Dividend 2024: € 584,491 ▲ 13% vs 2023 (€ 518,387) Unchanged	€ 1,221,077 Dividend 2025: € 1,221,077 ▲ 109% vs 2024 (€ 584,491) Unchanged	▲ 109%
Bank debt	€ 0 Bank debt 2022: € 0 First fiscal year in the series	€ 0 Bank debt 2023: € 0 Unchanged (€ 0) Unchanged	€ 33,800 Bank debt 2024: € 33,800 Unchanged (€ 0) Unfavourable step	€ 0 Bank debt 2025: € 0 ▼ 100% vs 2024 (€ 33,800) Favourable step	▼ 100%
Balance sheet total	€ 709,999 Balance sheet total 2022: € 709,999 First fiscal year in the series	€ 826,943 Balance sheet total 2023: € 826,943 ▲ 16% vs 2022 (€ 709,999) Unchanged	€ 665,892 Balance sheet total 2024: € 665,892 ▼ 19% vs 2023 (€ 826,943) Unchanged	€ 610,913 Balance sheet total 2025: € 610,913 ▼ 8% vs 2024 (€ 665,892) Unchanged	▼ 8%

Key figures of Van Looveren RX, radiologie BV, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Van Looveren RX, radiologie BV?

What happened at Van Looveren RX, radiologie BV in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Apr 28, 2026 New annual accounts for financial year 2025: profit of € 604,954 (▼ 2% vs 2024). Source: NBB ↗
Oct 8, 2019 New establishment in Schilde. KBO
2019 Kevin Van Looveren became a director. NBB
Oct 8, 2019 Start of the company according to the CBE. KBO

In short

From € 518,348 profit in 2022 to € 604,954 profit in 2025.

Paid € 761,963 in corporate taxes since 2022.

Best year ever: 2024, with € 616,123 profit.

Paid out € 3.2 million in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at Van Looveren RX, radiologie BV? We notify you, reason included.

Follow Van Looveren RX, radiologie BV

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit